Unlike many other cancers, most pancreatic tumors are rock hard.
“That’s one reason why pancreatic cancer is one of the most lethal types of cancer,” says Kenneth Olive, PhD, associate professor of medicine and pathology & cell biology at Columbia University Vagelos College of Physicians and Surgeons and a pancreatic cancer researcher at the Herbert Irving Comprehensive Cancer Center.
“Pancreatic tumors recruit a thick layer of connective tissue called stroma that hardens the tumor and acts like a shield,” says Olive, whose previous research first uncovered how the stroma makes it difficult for chemotherapy drugs to reach malignant cells. “As a result, most chemotherapy drugs can’t build up to the levels needed to be effective.”
To Olive, that suggests, paradoxically, a longer-lived—but less toxic—drug may work better.
“For a pancreatic cancer drug to be effective, it needs to stick around long enough to seep past the stroma and accumulate in the tumor. But if it is going to persist for a long time in the blood, it can’t be as toxic to the rest of the body,” he says.
Pancreatic Ductal Adenocarcinoma
Despite some recent improvements in pancreatic cancer treatment, the five-year survival rate for individuals with this disease is only around 9%.
Testing a New Drug Combination
Olive’s latest research, which was led by Jaime Eberle-Singh, PhD, while she was a graduate student at Columbia, may have identified a good candidate. The drug, an experimental compound called PTC596 that had shown antitumor activity in mouse and human pancreatic cancer cells, seemed to have the right qualities: PTC596 has a durable half-life (most cancer drugs have a half-life of a few minutes to hours) and can evade a pump that many cancer cells use to expel drugs. “This means that any amount of drug that makes it past the barrier can target the malignant cells,” says Olive.
Based on those studies, Olive, Eberle-Singh, and their collaborators tested PTC596 in combination with gemcitabine (a first-line drug for pancreatic cancer) in genetically engineered mice with an aggressive form of pancreatic cancer that is generally resistant to chemotherapy.
The mice that were treated with the two-drug combination lived three times longer than those treated with only a single standard agent. “This result was exciting because it’s exceedingly rare for any treatment to extend survival in this gold-standard mouse model,” Olive says.
They also tested PTC596 in combination with gemcitabine and another drug commonly used to treat pancreatic cancer, nab-paclitaxel, using human pancreatic tumors grown in mice. This combination further enhanced efficacy, making the tumors shrink outright.
“Based on the drug’s safety profile and our own findings, there’s a good rationale for testing PTC596 in combination with standard therapy in patients with pancreatic cancer,” says Olive.
Olive’s team also discovered that PTC596 blocks the formation of microtubules—a network of proteins involved in cell division and transport of nutrients within the cell. He demonstrated that PTC596 may act synergistically with nab-paclitaxel, another microtubule-binding agent.
“Combining different microtubule inhibitors has the potential to play an important role in the future of oncology, as there are many agents that each impact microtubules in different ways that could produce synergy,” Olive says.
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- UK to pilot blood test that may detect 50 types of canceron November 27, 2020 at 8:43 am
The UK's National Health Service (NHS) is to pilot a simple blood test that may detect more than 50 types of cancer and, it is hoped, could help thousands of people by allowing the disease to be ...
- Blood Test That Detects 50 Types of Cancer To Be Testedon November 27, 2020 at 5:32 am
Researchers hope the Galleri blood test will be a "gamechanger" for early cancer diagnosis, potentially saving many lives.
- NHS to trial blood test to detect more than 50 forms of canceron November 26, 2020 at 4:07 pm
The NHS is to trial a simple blood test that may help identify more than 50 forms of cancer years before diagnosis, in what it hailed as a potential “gamechanger”. If successful the blood test, known ...
- Pancreatic Cancer Therapeutics Diagnostics Market Growth Rate and Development Analysis to 2022on November 26, 2020 at 8:09 am
The uncontrolled growth of cells in the pancreas causes pancreatic cancer. It is an abnormal, unrestrained growth of ...
- Global Metastatic Pancreatic Cancer Treatment Market 2020 Size, Revenue, Growth Rate, Restraints, Forecast Analysis by 2025on November 24, 2020 at 3:10 pm
Global Metastatic Pancreatic Cancer Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025 published on MarketQuest.biz provides an in-depth analysis of industry- and ...
- Pancreatic cancer month - join the fight | Houghtaling and Downeyon November 24, 2020 at 3:46 am
By supporting research, staying vigilant about our own health and risk factors, and making our families and friends aware of this deadly disease, we will help drive the search for hope and a cure." ...
- U.S. pancreatic cancer deaths are expected to total 47,500 in 2020on November 23, 2020 at 6:08 pm
In 2020, deaths from pancreatic cancer in the United States are expected to total 47,500, according to the National Cancer Institute.
- November marks Pancreatic Cancer Awareness Monthon November 23, 2020 at 11:07 am
November is Pancreatic Cancer Awareness Month. Pancreatic cancer is extremely hard to detect and is the third leading cause of cancer-related deaths in the United States. Julie Fleshman, the president ...
- Alex Trebek spreads awareness about 'terrible' pancreatic cancer on pre-recorded 'Jeopardy!'on November 20, 2020 at 8:33 am
In honor of World Pancreatic Cancer Day, "Jeopardy!" aired a pre-recorded show featuring Alex Trebek's touching message about pancreatic cancer.
- The University of Verona and IntraOp® Announce PancFORT Trial for Pancreatic Canceron November 20, 2020 at 3:41 am
IntraOp Medical Corporation and the University of Verona in Italy announced today the enrollment of the first patient in the PancFORT Trial: A phase II study of primary chemotherapy, stereotactic body ...
via Bing News